Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo

Cancer Gene Therapy

Volumn 17, Issue 2, 2010, Pages 86-96

  Ardiani, A ^a   Sanchez Bonilla, M ^a   Black, M E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Fusion gene; Ganciclovir; Guanylate kinase; Suicide gene therapy; Thymidine kinase

Indexed keywords

GANCICLOVIR; GUANYLATE KINASE; HYBRID PROTEIN; MUTANT PROTEIN; OLIGONUCLEOTIDE; PRODRUG; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GLIOMA CELL; HERPES SIMPLEX VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SUICIDE GENE; TUMOR XENOGRAFT;

ANIMALS; ANTIVIRAL AGENTS; BYSTANDER EFFECT; CELL LINE, TUMOR; FEMALE; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC COMPLEMENTATION TEST; GLIOMA; GUANYLATE KINASE; MICE; MICE, NUDE; RATS; SIMPLEXVIRUS; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN HERPESVIRUS 1; MUS; RATTUS; SIMPLEXVIRUS;

EID: 74649083314     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.60     Document Type: Article

References (26)

1. Kokoris MS, Black ME. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 2002; 11: 2267-2272.
2. Moolten FL. Tumor sensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
3. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gen Med 2004; 6: 597-602.
4. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 1980; 255: 7204-7207.
5. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-tripho-sphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989; 264: 19039-19044.
6. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J et al. 9-([2-hydroxy-1-(hydroxymethyl)ethox-y]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983; 80: 4139-4143.
7. Greco O, Dachs G. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospective. J Cell Physiol 2001; 187: 22-36.
8. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997; 349: 2-3.
9. Kokoris MS, Sabo P, Black ME. Enhancement of tumor ablation by a selected HSV-thymidine kinase mutant. Gene Ther 1999; 6: 1415-1426.
10. Brady WA, Kokoris MS, Fitzgibbon M, Black M. Cloning, characterization, and modeling of mouse and human guanylate kinases. J Biol Chem 1996; 271: 16734-16740.
11. Boehme R. Phosphorylation of 9-b-D-arabinofuranosylgua-nine monophosphate by Drosophila melanogaster guanylate kinase. J Biol Chem 1984; 258: 12346-12349.
12. Ostermann N, Lavie A, Padiyar S, Brundiers R, Veit T, Reinstein J et al. Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 2000; 304: 43-53.
13. Fridland A, Connelly MC, Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymi-dine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol 1990; 37: 665-670.
14. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci USA 1996; 93: 3525-3529.
15. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001; 61: 3022-3026.
16. Willmon CL, Krabbenhoft E, Black ME. A guanylate kinase// HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther 2006; 13: 1309-1312.
17. Stolworthy TS, Krabbenhoft E, Black ME. A novel Escherichia coli strain allows functional analysis of guanylate kinase drug resistance and sensitivity. Anal Biochem 2003; 322: 40-47.
18. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CCG et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 57: 1523-1528.
19. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
20. Kaldor J, Day N, Pettersson F, Clarke E, Pederson D, Mehnest W et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6.
21. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354: 34-39.
22. Dachs GU, Tupper J, Tozer G. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359.
23. Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong Jy et al. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol 2005; 1: 115-123.
24. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997; 33: 1005-1016.
25. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 1997; 4: 577-585.
26. Akyurek L, Nallamshetty S, Aoki K, San H, Yang Z, Nabel G et al. Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo. Mol Ther 2001; 3: 779-786.